PLAINSBORO, N.J. – Novo Nordisk has announced a partnership with DJ Khaled to promote its weight-management medication Wegovy (semaglutide). The partnership highlights the musician’s personal experience with the GLP-1 treatment and encourages conversations about obesity care.
The collaboration, announced Thursday, November 12, follows Khaled’s use of Wegovy since late 2025. The musician and producer said he has lost 75 pounds, about 25% of his body weight, by combining the medication with dietary changes and physical activity.
“I’ve been taking Wegovy for a year now and lost 75 pounds, or about 25% of my body weight,” Khaled said. “My progress, it’s something I’m proud of, not just for myself, but what taking these steps means for my family.”
Through the campaign, Khaled will share details of his weight-loss journey, including his diet, exercise routine, and his decision to seek medical treatment. The initiative builds on his participation in Novo Nordisk’s Wegovy commercial, which aired during the 2026 Super Bowl.
The company said the partnership is part of a broader effort to highlight patients’ experiences with obesity medications and to encourage individuals to discuss available treatment options with health care professionals.
“This collaboration represents a new way for us to connect with people who are navigating their own health experiences,” said Ed Cinca, senior vice president of Marketing and Patient Solutions at Novo Nordisk. “DJ Khaled speaks directly to millions of people with honesty and energy, and we’re proud that he’s chosen to share something as personal as his experience with Wegovy.”
Wegovy is a prescription GLP-1 receptor agonist approved for chronic weight management in eligible patients when used with a reduced-calorie diet and increased physical activity. The medication is also approved to reduce the risk of major cardiovascular events in adults with established cardiovascular disease and obesity or overweight.
Novo Nordisk emphasized that Khaled’s results reflect his individual experience. In a 68-week clinical trial of 1,961 adults with obesity or overweight and a related medical condition, participants receiving Wegovy 2.4 mg achieved an average weight loss of 15%, compared with about 2.5% among those receiving a placebo.
Wegovy carries a boxed warning regarding the risk of thyroid C-cell tumors and is contraindicated in patients with a personal or family history of medullary thyroid carcinoma or multiple endocrine neoplasia syndrome type 2.
For more information about Wegovy® and the partnership with DJ Khaled, visit Wegovy.com/DJKhaled. To learn more about pricing options and coverage, visit novocare.com.
Please see Medication Guide and Prescribing Information, including Boxed Warning, for Wegovy® at https://www.novo-pi.com/wegovy.pdf.
Submit Your Press Release
Have news to share? Send us your press releases and announcements.
Send Press Release
